Lorlatinib
Back to searchMolecule Structure
Scientific Name
Lorlatinib
Description of the Drug
Lorlatinib is an anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12130
http://www.drugbank.ca/drugs/DB12130
Brand Name(s)
Lorbrena
Company Owner(s)
Pfizer Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| ALK tyrosine kinase receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL4247 |
| EML4-ALK | CHIMERIC PROTEIN | INHIBITOR | CHEMBL3883330 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL15261807 | |
| DrugBank | DB12130 | |
| PubChem | 71731823 | |
| Nikkaji | J3.339.850F | |
| PDBe | 5P8 | |
| BindingDB | 50018830 | |
| DrugCentral | 5302 | |
| ChemicalBook | CB02716543 | |
| Guide to Pharmacology | 7476 | |
| rxnorm | LORBRENA | LORLATINIB |
| ChEBI | 143117 | |
| ZINC | ZINC000098208524 |
